Therapeutic IL-6 R-antibody from the original RoActemra® commercial drug targeting the IL-6 R-antigen, also referred to as RoActemra® or tocilizumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.
Easy Access
Easy to order as license-free research consumable
Multiple batches
Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs
Up to 80% less compared to the original pharmaceutical price
Prompt delivery
Shipment within days worldwide according to GDP-standards
Documented origin
Information on batch, registration number, expiry date, GDP-compliant pedigree
What our clients say
Anjan Selz
Vice President
Head of Biosimilars EMEA
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
Thibault Jonckheere
CEO
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
Tom H. Jin, M.D.
Director of Process Development
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
Prof. Dr. Henning von Horsten
Life Science Engineering, HTW Berlin
“Evidentic gives rapid access to originator biologics and different batches. For biosimilar developers and regulators, it will shorten the time to gauge the analytical acceptance range for multiple CQAs of biotherapeutics.”
Tocilizumab/ RoActemra
Product Reference
| Drug name | RoActemra® |
| INN | Tocilizumab |
| API type | humanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology |
| Pharmacotherapeutic group | Immunosuppressants, Interleukin inhibitors |
| ATC code | L04AC07 |
| Target of antibody | IL-6 R; Synonyms: IL6R, il-6ra, CD126, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80, IL6R1, Il6ra, IL-6Ralpha, IL6R, Il6r |
| General function | |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). Tocilizumab has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed. Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability. In tocilizumab-treated patients, decreases in the levels of CRP to within normal ranges were seen as early as week 2, with decreases maintained while on treatment. In healthy subjects administered tocilizumab in doses from 2 to 28 mg/kg, absolute neutrophil counts decreased to their lowest 3 to 5 days following administration. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. Rheumatoid arthritis patients demonstrated a similar pattern of absolute neutrophil counts following tocilizumab administration (see section 4.8). |
| Original license holder | |
| Marketing authorisation numbers | EU/1/08/492/001 - 008 |
| Marketing authorisation holder | Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom |
| Name of the manufacturer of the biological active substance | Chugai Pharma Manufacturing Co., Ltd. 16-3 Kiyohara Kogyodanchi Utsunomiya City Tochigi, 321-3231 Japan Genentech Inc. One Antibody Way Oceanside CA 92056 USA |
| Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Germany |
| Max shelf life | 30 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose Polysorbate 80 Disodium phosphate dodecahydrate Sodium dihydrogen phosphate dihydrate Water for injections |
